Overall outcomes of NMA haplo BMT with high-dose posttransplantation cyclophosphamide. (A) Progression-free and overall survival. (B-D) Cumulative incidences by competing-risk analysis of relapse and nonrelapse mortality (B), acute graft-versus-host disease (C), and any chronic graft-versus-host disease (D). Point estimates are provided in Table 2.